PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial

CONCLUSION: PAM-50 can be used as a prognostic tool for local recurrence risk in postmenopausal women with hormone receptor-positive breast cancer treated with endocrine therapy. The test was not predictive for the benefit of radiotherapy.PMID:33608712 | DOI:10.1093/bjs/znaa089

Source: The British Journal of Surgery - February 20, 2021 Category: Surgery Authors: F Fitzal M Filipits C Fesl M Rudas R Greil M Balic F Moinfar W Herz P Dubsky R Bartsch S Ferree C Schaper M Gnant Source Type: research